Alzheimers disease dementia
Conditions
Interventions
32 sessions of 20 Hz rTMS over the precuneus: a 2-week intensive phase with
daily (5x/week) rTMS, followed by a 22-week maintenance phase with weekly rTMS.
Sponsors
Amsterdam UMC
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Biomarker-supported Alzheimer*s disease (Abnormal CSF p-tau/Aß42 ratio of > 0.023 or Amyloid PET positive). - Between 50 and 85 years old. - Clinical dementia rating (CDR) score of 0.5 or 1 {Morris, 1993 #80}. - Mini-mental state examination (MMSE) score between 18 and 27. - Presence of a caregiver.
Exclusion criteria
Exclusion criteria: - Medical history of other neurodegenerative diseases, stroke, or epilepsy. - Severe psychiatric dysregulation, hampering successful study participation and leading to possible cognitive impairment. Eligibility for participation will be based on clinical evaluation by an expert neurologist and/or psychiatrist. - Extensive cerebrovascular damage on MRI classified as Fazekas level 2 or 3. Patients with abnormalities classified as Fazekas level 3 are excluded {Fazekas F Fau - Chawluk, #115}. For Fazekas level 2, patient*s eligibility for participation will be evaluated by an expert neurologist. - Presence of metal in the head or cranial/thoracic implants, including cochlear implants. - Cholinesterase inhibitors with unstable d osage in the last 2 months. - Extreme claustrophobia or metallic objects in or on the body, preventing MRI and MEG examination. - Previous rTMS treatment (for blinding reasons).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome will be the pre-to-post difference in clinical dementia rating, as measured with the clinical dementia rating - sum of boxes scale (CDR-SB), in the real rTMS condition compared to the sham condition. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcome measures include additional cognitive and clinical rating scales, neuropsychological assessment batteries, magnetoencephalography, and cerebrospinal fluid biomarkers. | — |
Countries
Netherlands
Contacts
Public ContactHJ Woerdman
Amsterdam UMC
Outcome results
None listed